Oncare is a cancer care startup based in Gurugram, India, that runs a distributed oncology platform offering affordable, standardised cancer treatment through partner hospitals for patients.

This Startup Deep Dive explains what Oncare does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Oncare in Brief

• What it is: Oncare is an Indian Distributed oncology care company based in Gurugram.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Oncare operates a distributed oncology care platform offering medical, surgical and radiation oncology under one platform through accredited partner hospitals.
• It partners with 50-100-bed hospitals to set up dedicated oncology wings in underused space and claims treatment costs up to 40% lower (company-stated).
• The company says chemotherapy is priced at roughly Rs 24,000-25,000 per session versus about Rs 40,000 at corporate hospitals (company-stated).
• Funding: About $1 million seed plus Series A of Rs 27 crore (about $3-4 million; reports differ).

Oncare Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Oncare?

Oncare operates in the Distributed oncology care space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Oncare.

• Oncare operates a distributed oncology care platform offering medical, surgical and radiation oncology under one platform through accredited partner hospitals.
• It partners with 50-100-bed hospitals to set up dedicated oncology wings in underused space and claims treatment costs up to 40% lower (company-stated).
• The company says chemotherapy is priced at roughly Rs 24,000-25,000 per session versus about Rs 40,000 at corporate hospitals (company-stated).
• It runs four centres in Delhi NCR.

The Origin Story of Oncare

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Amar Sneh, Deepak Kumar.
• Founded in 2023 by Amar Sneh and Deepak Kumar, described as former executives at Pristyn Care.
• The legal entity is Aedos Health Solutions Pvt Ltd, trading as Oncare.
• The first centre was in South Delhi; Ghaziabad opened on 1 October 2024 and a West Delhi centre was planned for 1 November 2024.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Distributed oncology care sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2023: company founded.
• October 2024: $1 million seed led by Huddle Ventures; about 2,500 patients guided and over 500 treatment sessions in about 10 months (company-stated).
• October 2024: Ghaziabad centre launched.
• February 2026: Series A of Rs 27 crore led by Sky Impact Capital.
• Four centres in Delhi NCR as of the Series A.

Oncare Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• October 2024: $1 million seed led by Huddle Ventures, with TRTL Ventures, Cloud Capital and DeVC.
• February 2026: Series A of Rs 27 crore (about $4 million per one outlet, about $3 million per another) led by Sky Impact Capital, with Huddle Ventures, Lotus Herbal Group, SteerX and Tremis Capital; one outlet names Elevation Capital as lead, so reports differ.

How Does Oncare Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Asset-light model: partner with accredited mid-sized hospitals to run dedicated oncology units rather than build hospitals.
• Revenue from treatment services at lower prices than corporate hospitals, where treatment can exceed Rs 10 lakh.
• Series A funds go to new metros, tier-II and tier-III cities and clinical operations technology.

The Numbers: Oncare Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24: operating income about Rs 67 lakh and net loss about Rs 23 lakh (reported by a deal database).
• Cost reduction of up to 40% claimed (company-stated).
• Four centres; about 2,500 patients guided and over 500 sessions as of late 2024 (company-stated).

Market Opportunity for Oncare

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Oncology delivery through hospital partnerships in Indian metros and, planned, tier-II and tier-III cities.
• Seed plans called for 10 new centres across Delhi NCR, Bengaluru and Jaipur within two years; Series A plans cite Bengaluru and cities in Uttar Pradesh, Bihar and West Bengal.

Technology and Product at Oncare

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Series A funds are planned partly for technology supporting clinical operations, care coordination and patient experience.

Team and Culture at Oncare

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Co-founders Amar Sneh and Deepak Kumar, ex-Pristyn Care.
• Plans to grow clinical and administrative teams.

Oncare Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Oncare

• The model depends on partnerships with hospitals, and the footprint is still four centres in Delhi NCR.
• Quality and clinical outcome control across partner sites is a challenge for an asset-light model.
• Funding details conflict between outlets on lead investor and dollar value.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Oncare Growth Outlook: What to Watch

• Seed plans called for 10 new centres across Delhi NCR, Bengaluru and Jaipur over two years.
• Series A funds are meant for entry into new metro markets, tier-II and tier-III cities, and clinical operations technology.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Oncare can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Oncare Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Oncare

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Oncare.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Oncare

Studying a company in the Distributed oncology care space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Oncare.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Oncare as a Startup

• Customer clarity: Can Oncare name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Oncare is part of India’s growing Distributed oncology care ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Oncare FAQs: Frequently Asked Questions

What is Oncare?

Oncare is a cancer care startup based in Gurugram, India, that runs a distributed oncology platform offering affordable, standardised cancer treatment through partner hospitals for patients. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Oncare?

Oncare was founded by Amar Sneh, Deepak Kumar, and the company reports a founding year of 2023.

How much funding has Oncare raised?

About $1 million seed plus Series A of Rs 27 crore (about $3-4 million; reports differ). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Oncare make money?

Oncare earns revenue from its Distributed oncology care products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Oncare?

Reported rivals include 4baseCare, Everhope Oncology, MOC Cancer Care & Research Centre, Corporate hospital chains. See the competitor comparison above for how they differ.

What are the main risks for Oncare?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Ring — RING: Kissht operator OnEMi reported FY25 profit of Rs 161 crore and filed for a Rs 1,000 crore IPO | MedPiper — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.